KRAS and non-small cell lung carcinoma: We investigated the impact of MRTX849 treatments (1 μM for 1 and 7 days) on the SRC/JUN/ABCC1 pathways in KRAS-G12C–mutant NSCLC cell lines HOP62 and H2030.